How to make sure we all benefit when nonprofits patent technologies like CRISPR; The Conversation via The Associated Press via WTOP, July 19, 2017

The Conversation via The Associated Press via WTOP; How to make sure we all benefit when nonprofits patent technologies like CRISPR

"(The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.)

Shobita Parthasarathy, University of Michigan

(THE CONVERSATION) Universities and other nonprofit research institutions are under increasing fire about their commitments to the public interest. In return for tax-exempt status, their work is supposed to benefit society.

But are they really operating in the public interest when they wield their patent rights in ways that constrict research? Or when potentially lifesaving inventions are priced so high that access is limited? The public partially underwrites nonprofit discoveries via tax breaks and isn’t seeing a lot of benefit in return.

Questions like these arose recently in the case of CRISPR, the promising new gene-editing technology. After patenting it, the Broad Institute of MIT and Harvard sold the exclusive right to develop CRISPR-based therapies to its sister company Editas Medicine. Critics worry that this monopoly could limit important research and result in exorbitant prices on emerging treatments."